Corynn Kasap, MD, PhD
Clinical Fellow
Medicine
School of Medicine

Publications (8)

Top publication keywords:
EndonucleasesQuinazolinesFusion Proteins, bcr-ablNaphthoquinonesBenzamidesMultiple MyelomaProto-Oncogene Proteins c-ablImidazolesAntineoplastic AgentsLeukemia, Myeloid, AcuteDrug Resistance, NeoplasmProtein-Tyrosine KinasesReceptors, CytokineClustered Regularly Interspaced Short Palindromic RepeatsHigh-Throughput Nucleotide Sequencing

• Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cells.
  bioRxiv : the preprint server for biology 2024 Kasap C, Izgutdina A, Patiño-Escobar B, Kang A, Chilakapati N, Akagi N, Johnson H, Rashid T, Werner J, Barpanda A, Geng H, Lin YT, Rampersaud S, Gil-Alós D, Sobh A, Dupéré-Richer D, Wicaksono G, …
• Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target.
  Nature cancer 2023 Mandal K, Wicaksono G, Yu C, Adams JJ, Hoopmann MR, Temple WC, Izgutdina A, Escobar BP, Gorelik M, Ihling CH, Nix MA, Naik A, Xie WH, Hübner J, Rollins LA, Reid SM, Ramos E, Kasap C, Steri V, Serrano …
• Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
  Cell chemical biology 2022 Ferguson ID, Lin YT, Lam C, Shao H, Tharp KM, Hale M, Kasap C, Mariano MC, Kishishita A, Patiño Escobar B, Mandal K, Steri V, Wang D, Phojanakong P, Tuomivaara ST, Hann B, Driessen C, Van Ness B, …
• The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance.
  Nature communications 2022 Ferguson ID, Patiño-Escobar B, Tuomivaara ST, Lin YT, Nix MA, Leung KK, Kasap C, Ramos E, Nieves Vasquez W, Talbot A, Hale M, Naik A, Kishishita A, Choudhry P, Lopez-Girona A, Miao W, Wong SW, Wolf JL…
• DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.
  Nature chemical biology 2014 Kasap C, Elemento O, Kapoor TM
• Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.
  Cancer cell 2012 Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X, Chen SC, Payne-Turner D, Churchman ML, Harvey RC, Chen X, Kasap C, Yan C, Becksfort J, Finney RP, Teachey DT, Maude SL, Tse K, Moore R, Jones S, …
• Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
  Cancer research 2009 Seeliger MA, Ranjitkar P, Kasap C, Shan Y, Shaw DE, Shah NP, Kuriyan J, Maly DJ
• Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
  Cancer cell 2008 Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E, Nicaise C, Sawyers CL